Clinical-translational programmes are being structured in hepatocellular carcinoma, colorectal cancer and pancreatic cancer, integrating patient-linked biospecimens, biomarker discovery and functional translational models.
Imperion Biotechnology is developing clinical-translational research pathways with Memorial Hospitals across key oncology areas including hepatocellular carcinoma, colorectal cancer and pancreatic cancer.
These programmes are designed to integrate clinically annotated patient data, biospecimen workflows, serum-linked biomarkers, ctDNA-oriented molecular profiling, epigenetic analysis, tissue-based interpretation and organoid-linked functional evaluation.
The long-term objective is to support reusable precision-oncology workflows and contribute to the establishment of stronger translational medicine capacity in Türkiye.